Literature DB >> 18332879

Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania.

G Shaltiel1, S Maeng, O Malkesman, B Pearson, R J Schloesser, T Tragon, M Rogawski, M Gasior, D Luckenbaugh, G Chen, H K Manji.   

Abstract

The glutamate receptor 6 (GluR6 or GRIK2, one of the kainate receptors) gene resides in a genetic linkage region (6q21) associated with bipolar disorder (BPD), but its function in affective regulation is unknown. Compared with wild-type (WT) and GluR5 knockout (KO) mice, GluR6 KO mice were more active in multiple tests and super responsive to amphetamine. In a battery of specific tests, GluR6 KO mice also exhibited less anxious or more risk-taking type behavior and less despair-type manifestations, and they also had more aggressive displays. Chronic treatment with lithium, a classic antimanic mood stabilizer, reduced hyperactivity, aggressive displays and some risk-taking type behavior in GluR6 KO mice. Hippocampal and prefrontal cortical membrane levels of GluR5 and KA-2 receptors were decreased in GluR6 KO mice, and chronic lithium treatment did not affect these decreases. The membrane levels of other glutamatergic receptors were not significantly altered by GluR6 ablation or chronic lithium treatment. Together, these biochemical and behavioral results suggest a unique role for GluR6 in controlling abnormalities related to the behavioral symptoms of mania, such as hyperactivity or psychomotor agitation, aggressiveness, driven or increased goal-directed pursuits, risk taking and supersensitivity to psychostimulants. Whether GluR6 perturbation is involved in the mood elevation or thought disturbance of mania and the cyclicity of BPD are unknown. The molecular mechanism underlying the behavioral effects of lithium in GluR6 KO mice remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332879      PMCID: PMC2804880          DOI: 10.1038/mp.2008.20

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  54 in total

Review 1.  Subcellular localization and trafficking of kainate receptors.

Authors:  Frédéric Jaskolski; Françoise Coussen; Christophe Mulle
Journal:  Trends Pharmacol Sci       Date:  2005-01       Impact factor: 14.819

2.  In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

3.  Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice.

Authors:  C Mulle; A Sailer; I Pérez-Otaño; H Dickinson-Anson; P E Castillo; I Bureau; C Maron; F H Gage; J R Mann; B Bettler; S F Heinemann
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus.

Authors:  A Rodríguez-Moreno; O Herreras; J Lerma
Journal:  Neuron       Date:  1997-10       Impact factor: 17.173

5.  A complex mosaic of high-affinity kainate receptors in rat brain.

Authors:  W Wisden; P H Seeburg
Journal:  J Neurosci       Date:  1993-08       Impact factor: 6.167

Review 6.  The validity of animal models of depression.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Animal model of depression. I. Review of evidence: implications for research.

Authors:  W T McKinney; W E Bunney
Journal:  Arch Gen Psychiatry       Date:  1969-08

8.  The kainate receptor subunit GluR6 mediates metabotropic regulation of the slow and medium AHP currents in mouse hippocampal neurones.

Authors:  André Fisahn; Stephen F Heinemann; Chris J McBain
Journal:  J Physiol       Date:  2004-11-11       Impact factor: 5.182

Review 9.  The physiological role of kainate receptors in the amygdala.

Authors:  Maria F M Braga; Vassiliki Aroniadou-Anderjaska; He Li
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

10.  Regulation of dopaminergic transmission and cocaine reward by the Clock gene.

Authors:  Colleen A McClung; Kyriaki Sidiropoulou; Martha Vitaterna; Joseph S Takahashi; Francis J White; Donald C Cooper; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

View more
  77 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

2.  Reversal of hippocampal neuronal maturation by serotonergic antidepressants.

Authors:  Katsunori Kobayashi; Yumiko Ikeda; Atsushi Sakai; Nobuyuki Yamasaki; Eisuke Haneda; Tsuyoshi Miyakawa; Hidenori Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

3.  Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans.

Authors:  David T Dao; Pamela Belmonte Mahon; Xiang Cai; Colleen E Kovacsics; Robert A Blackwell; Michal Arad; Jianxin Shi; Peter P Zandi; Patricio O'Donnell; James A Knowles; Myrna M Weissman; William Coryell; William A Scheftner; William B Lawson; Douglas F Levinson; Scott M Thompson; James B Potash; Todd D Gould
Journal:  Biol Psychiatry       Date:  2010-08-17       Impact factor: 13.382

Review 4.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 5.  Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders.

Authors:  Katsunori Kobayashi
Journal:  Mol Neurobiol       Date:  2009-01-08       Impact factor: 5.590

Review 6.  Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.

Authors:  Greg C Carlson
Journal:  Pharmacol Biochem Behav       Date:  2011-02-16       Impact factor: 3.533

7.  Altered GluA1 (Gria1) Function and Accumbal Synaptic Plasticity in the ClockΔ19 Model of Bipolar Mania.

Authors:  Puja K Parekh; Darius Becker-Krail; Poornima Sundaravelu; Shinsuke Ishigaki; Haruo Okado; Gen Sobue; Yanhua Huang; Colleen A McClung
Journal:  Biol Psychiatry       Date:  2017-06-27       Impact factor: 13.382

8.  Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.

Authors:  Daniel P Dickstein; Kenneth E Towbin; Jan Willem Van Der Veen; Brendan A Rich; Melissa A Brotman; Lisa Knopf; Laura Onelio; Daniel S Pine; Ellen Leibenluft
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-02       Impact factor: 2.576

9.  Kainate Receptors Inhibit Glutamate Release Via Mobilization of Endocannabinoids in Striatal Direct Pathway Spiny Projection Neurons.

Authors:  John J Marshall; Jian Xu; Anis Contractor
Journal:  J Neurosci       Date:  2018-03-14       Impact factor: 6.167

10.  Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?

Authors:  Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes
Journal:  Neurobiol Dis       Date:  2010-08-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.